ZARR

News and price dashboard

Swept 05:46
Sources
27, all reachable
Items
76960
Flagged
9666
Last swept
05:46

STOCKS

121

OPTIONS

25

COMING UP

US majors and your names' earnings, next 7 days

Full calendar

Everything else — unscored, browse only, never pushed

Brief

Feed shape today

This is the unfiltered general feed: 200 items, and the overwhelming majority are routine Investing.com 8-K notices, Form 4 insider filings, TradingView chart posts and Nasdaq option-activity screens with no substance behind them. Twenty were read in full, and of those, most are the same automated "stock hits 52-week high/low" template run twice across the UK and US editions of Investing.com, so the duplicate pairs are one story each, not two.

A cluster of 52-week lows

The biggest single theme in the read items is a run of new 52-week lows. T-Mobile hit $147.89, down 32% over the year and 34.5% off its $225.93 high, with the ticker line showing TMUS down 7.70%. The article gives no reason for the day's drop, but notes earnings due October 28 and a string of recent broker notes: Raymond James upgraded to Outperform arguing SpaceX competition fears are overdone, KeyBanc stayed Overweight on possible upside in average revenue per account despite slightly higher churn from pricing actions, StoneX reiterated Buy on AI implementation, and JPMorgan cut its target to $260 from $275 while keeping Overweight and trimming revenue estimates to line up with T-Mobile's $19.30bn wireless service revenue guidance. NewAmsterdam Pharma touched $19.55, down 44.92% on the year with the ticker showing NAMS off 8.67%, against a $2.35bn market cap; the piece cites EU approval of its obicetrapib/ezetimibe fixed-dose combination, Stifel holding Buy and a $50 target after the failure of Novartis's HORIZON trial, RBC cutting to $42 from $50 over the Phase III PREVAIL interim analysis at a 35-38% estimated probability of success, and CEO Michael Davidson buying 10,000 shares for $226,500. MGM Resorts hit $27.93 against a $51.59 high, shown down 4.97%, with earnings five days out; the context given is Macau gaming revenue projected by Jefferies to fall 6-10% in October, a $107m room renovation disrupting Borgata, and Mizuho cutting its target to $55 from $60 after People Inc. withdrew its bid for the shares it doesn't own. Two more lows are quieter: Huntington Bancshares' 4.500% Series H preferred at $14.90, down 18.73% over the year on a 7.51% yield and a 56-year dividend record, and Selective Insurance Group's SIGIP preferred at $14.74, down 16.42%, yielding 7.75% with 52 straight years of dividends. Neither article gives a specific cause beyond general rate and financial-sector pressure.

The two highs, and what's behind them

Going the other way, Amerant Bancorp hit a 52-week high of $30.65, up 77.42% over a year and 53.72% year to date on a $1.2bn market cap, after Q3 2026 diluted EPS of $0.65 against the $0.57 consensus, revenue of $108.8m versus $103.35m expected, net income of $25.7m and a 1.0% return on assets, its best on that measure since 2022. Safety Insurance Group set an all-time high at $104.16, up 56% over the year, and the reason is specific: the Hart-Scott-Rodino waiting period on its merger with MAPFRE U.S.A. has expired, clearing a condition for the deal announced on 23 July 2026, under which Splash Merger Sub merges into Safety and the company becomes a MAPFRE subsidiary.

Macy's dividend

The only other full-text item with real content is Macy's declaring a regular quarterly dividend of 19.15 cents per share, payable 4 January 2027 to holders of record on 15 December 2026.

Filings with nothing attached

Four full-text items turned out to be bare 8-K notices with no body text at all: Ionis Pharmaceuticals, Zevia, Unity Software and Visa, all dated 23 October. There is nothing in them to read beyond the fact that a filing exists.

What the headline-only remainder contains

The rest is headlines only, so take them as stated and nothing more. Earnings coverage runs through regional banks and REITs: Preferred Bank beat on Q3 EPS with shares slipping premarket, First Hawaiian missed as shares fell with NIM gains offset by credit costs, WSFS beat with wealth revenue up 30% and ROTCE at 20.7%, and Kilroy Realty raised guidance on record leasing. On biotech, Roche's sefaxersen is reported to have shown a 43% proteinuria reduction in an IgA nephropathy trial, with Ionis named as partner, Vertex reported positive IgAN data with an FDA decision due 30 November, and the FDA approved a subcutaneous induction regimen for AbbVie's Skyrizi. Several analyst headlines sit unread: Jefferies raising Zymeworks on the Roche deal, Williams Trading cutting Deckers on weak DTC trends, RBC reiterating Outperform on Verisk, and Raymond James reiterating Strong Buy on Alnylam. On trade, two separate headlines say the US is expected to lift 50% tariffs on some Canadian agricultural and forestry goods, one framing it as relief for trade-dependent states. Commodities headlines point to cocoa falling on rising ICE inventories and higher Nigerian exports, coffee falling despite inventories at a five-week low, sugar supported by lower Brazilian production, and Indian crude imports up 16% in September. The remainder is chart-idea posts, option-activity screens, consensus-target adjustments and political social media, none of which carries anything beyond its own title.

20 read in full, 200 items in the section

Feed

162 stories · 162 newCross-publisher stories only
  1. Pinned
  2. 162 new
  3. XAUUSD Weekly: 4,000 Lost — Is 3,930 the Trap?
    TradingView [COMMENT]
  4. BTCUSDT: Trendline Breakdown Eyes $75K Liquidity
    TradingView [COMMENT]
  5. Form 4 iShares Semiconductor ETF For: 24 October
    Investing.com - UK 2 items
  6. Why Traders Overcomplicate Simple Setups
    TradingView [COMMENT]
  7. Gold Long-Term Outlook
    TradingView [COMMENT] 2 itemsalso TradingView
  8. 5 Habits That Keep You Ahead of the Market
    TradingView [COMMENT]
  9. Silver Long-Term Outlook: Potential Bottom Around $43–45
    TradingView [COMMENT] 2 itemsalso TradingView
  10. Crypto Rotation: Follow the Profit Flow
    TradingView [COMMENT]
  11. Form 4 JOHN WILEY & SONS: Inder M. Singh (Director) For: 22 October
    Investing.com - UK 6 itemsalso Investing.com - UK
  12. Gold Under $4,000 — Is the Next Rally a Trap?
    TradingView [COMMENT]
  13. Form 144 Maplebear Inc. For: 23 October
    Investing.com - UK 5 items
  14. XAUUSD: Gold Below $4,000 — Is the Next Bounce a Trap?
    TradingView [COMMENT] 2 items
  15. Form DEF 14A Xylem Inc For: 23 October
    Investing.com - UK 2 items
  16. Track the Whales Before the Move
    TradingView [COMMENT]
  17. Form 13D/A Silvia For: 23 October
    Investing.com - UK 3 itemsalso Investing.com - UK
  18. Form 4 FTC Solar Inc: Antonio R. Alvarez (Director) For: 22 October
    Investing.com - UK 6 itemsalso Investing.com - UK
  19. MSFT Microsoft Corporation Options Ahead of Earnings
    TradingView [COMMENT] 3 itemsalso TradingView
  20. COIN Coinbase Global Options Ahead of Earnings
    TradingView [COMMENT]
  21. fcpo
    TradingView [COMMENT]
  22. BITCOIN (BTC) — THE $80K BATTLE
    TradingView [COMMENT]
  23. US30 sell technical analysis
    TradingView [COMMENT]
  24. Form 144 Grayscale Horizen Trust (ZEN) For: 23 October
    Investing.com - UK 3 itemsalso Investing.com - UK
  25. Form 4 Quest Diagnostics orporated: Vicky B. Gregg (Director) For: 21 October
    Investing.com - UK 4 itemsalso Investing.com - UK
  26. XAUUSD — Value Acceptance Around 3,995
    TradingView [COMMENT]
  27. CCI system construction: DJT weekly scale
    TradingView [COMMENT]
  28. AMZN Amazon Options Ahead of Earnings
    TradingView [COMMENT]
  29. Form 4 Silvia, Inc: Renae Terese Cormier (Former Chief Financial Officer) For: 21 October
    Investing.com - UK 2 itemsalso Investing.com - UK
  30. GOOGL Alphabet Options Ahead of Earnings
    TradingView [COMMENT]
  31. Vertex at ASN Kidney Week 2026: renal push gathers pace
    Investing.com - UK 2 itemsalso Investing.com - news
  32. Form 4 The Greenbrier Companies, Inc: Michael J. Donfris (SVP, CFO) For: 21 October
    Investing.com - UK 6 itemsalso Investing.com - UK
  33. W Marks the Spot: Pyth Network Retest Incoming!
    TradingView [COMMENT]
  34. ZKC Potential playout
    TradingView [COMMENT]
  35. BTC is approaching the box again
    TradingView [COMMENT]
  36. Therma Bright plans private placement of up to $420,000
    Investing.com - news 2 itemsalso Investing.com - UK
  37. SOLANA SHALLOW WAVE 2 CONFIRMED
    TradingView [COMMENT]
  38. Goldcana closes C$1 million flow-through private placement
    Investing.com - news 2 itemsalso Investing.com - UK
  39. Cathie Wood’s ARK sells Alphabet stock, buys Freenome shares
    Investing.com - UK 2 itemsalso Investing.com - news
  40. FRMI Fermi: An AMD-Backed AI Power Play
    TradingView [COMMENT]
  41. Bear Pennant Under 4000 After the Weekly Close - Next Stop 3975/
    TradingView [COMMENT] 2 itemsalso TradingView
  42. BTC/USD – BUY THE SUPPORT, TARGET $84,000
    TradingView [COMMENT]
  43. Wheat Bulls Fail to Find Footing on Friday
    Nasdaq - stocks 2 items
  44. Cotton Slip Lower into the Weekend
    Nasdaq - stocks
  45. Soybeans Post Friday Gains
    Nasdaq - stocks 2 items
  46. BTC | Daily
    TradingView [COMMENT]